RxDataLab

Sign In Get Started

app.rxdatalab.com · Free public feature

Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.

Get Full Access Today → Login →

BioHedge

Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades. Free public view — the full platform adds company profiles, trial history, competitive landscape, and financing tracker for 500+ biotech companies.

Filings through May 18, 2026
Updated continuously
Weekly recaps → Strategic Signals → What are these? ↓

Activity Summary

Last 60 Days
2
13D Filings
3
New Positions
2
Exits
3
Increased
9
Decreased
9
Funds Active

Multi-Fund Activity

Companies with two or more institutional investors filing in the same period.

Accumulating
PRLD Prelude Therapeutics Inc
▲1.9
3 funds
RA Capital Management ▲9.9 , OrbiMed , Baker Brothers Advisors ▼-8.0
RLYB Rallybio Corp
▲7.6
2 funds
Cormorant Asset Management, LP ▲7.6 , 5AM Ventures
ATRA ATARA BIOTHERAPEUTICS INC
▲7.5
2 funds
Redmile Group , EcoR1 Capital ▲7.5
SYRE Spyre Therapeutics, Inc.
▲5.0
2 funds
Perceptive Advisors ▲5.0 , Fairmount Funds Management LLC
GLUE Monte Rosa Therapeutics, Inc.
▲3.7
2 funds
Baker Brothers Advisors ▲3.3 , BVF Partners L.P. ▲0.4
Reducing
AVTX Avalo Therapeutics, Inc.
▼-4.3
3 funds
RA Capital Management, OrbiMed ▼-4.3, BVF Partners L.P.
TRAW Traws Pharma, Inc.
▼-11.9
2 funds
Perceptive Advisors ▼-3.9, OrbiMed ▼-8.0
MLTX MoonLake Immunotherapeutics
▼-5.2
2 funds
Cormorant Asset Management, LP ▲0.2, BVF Partners L.P. ▼-5.4
TENX TENAX THERAPEUTICS, INC.
▼-3.6
2 funds
BVF Partners L.P., Perceptive Advisors ▼-3.6
HOWL Werewolf Therapeutics, Inc.
▼-2.8
2 funds
RA Capital Management ▼-1.2, MPM BioImpact ▼-1.6

Filing Volume by Week

13D 13G
D BVF Partners L.P.
May 18, 2026
XOMA XOMA ROYALTY CORPORATION
43.3% ▲21.9 19d
G Cormorant Asset Management, LP
May 15, 2026
RLYB Rallybio Corp
7.6% NEW
G Cormorant Asset Management, LP
May 15, 2026
MLTX MoonLake Immunotherapeutics
6.2% ▲0.2 87d
G EcoR1 Capital
May 15, 2026
VYGR VOYAGER THERAPEUTICS INC
0.0% EXIT 87d
G Cormorant Asset Management, LP
May 15, 2026
enGene Holdings Inc.
0.0% EXIT
G EcoR1 Capital
May 15, 2026
MREO MEREO BIOPHARMA GROUP PL-ADR
8.4% ▼-1.0 126d
G Cormorant Asset Management, LP
May 15, 2026
BIOA BIOAGE LABS INC
6.5% ▲0.8 87d
G Cormorant Asset Management, LP
May 15, 2026
CABA CABALETTA BIO INC
9.0% ▼-0.2 87d
G Cormorant Asset Management, LP
May 15, 2026
RAPP Rapport Therapeutics Inc.
6.2% ▼-0.2 87d
G EcoR1 Capital
May 15, 2026
XNCR Xencor Inc
2.9% ▼-3.5 87d
D BIOS Partners
May 15, 2026
LTRN Lantern Pharma Inc.
4.5% ▼-2.9 29d
G Baker Brothers Advisors
May 15, 2026
PRAX Praxis Precision Medicines, Inc.
6.3% NEW
G MPM BioImpact
May 15, 2026
FBRX Forte Biosciences, Inc.
7.2% NEW
G BVF Partners L.P.
May 15, 2026
FHTX Foghorn Therapeutics Inc.
10.0%
G BVF Partners L.P.
May 15, 2026
ELDN ELEDON PHARMACEUTICALS INC
10.0%
G RA Capital Management
May 15, 2026
CTNM Contineum Therapeutics
4.0% ▼-3.2 87d
G BVF Partners L.P.
May 15, 2026
TCRX TScan Therapeutics, Inc.
10.0% 365d
G Perceptive Advisors
May 15, 2026
AMLX Amylyx Pharmaceuticals, Inc.
7.5% ▼-0.7 182d
G Perceptive Advisors
May 15, 2026
IKT INHIBIKASE THERAPEUTICS INC
8.9% ▼-1.1 87d
G RA Capital Management
May 15, 2026
FDMT 4D Molecular Therapeutics, Inc.
9.9% 87d
G BVF Partners L.P.
May 15, 2026
FDMT 4D Molecular Therapeutics, Inc.
10.0% 87d
G BVF Partners L.P.
May 15, 2026
ANNX Annexon, Inc.
5.4%
G Redmile Group
May 15, 2026
SRRK Scholar Rock Holding Corp
7.6% ▼-2.3 455d
G BVF Partners L.P.
May 15, 2026
CGEM Cullinan Therapeutics, Inc.
10.0% 87d
G RA Capital Management
May 15, 2026
PALI PALISADE BIO INC
9.9%

Understanding Schedule 13D and 13G Filings

Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.

Schedule 13D (Activist)

Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.

Schedule 13G (Passive)

Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.

Gap column: Days since previous filing for the same fund+company pair.

Data source: SEC EDGAR. Filings typically available within 4 hours of submission.

This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.

Intelligence Platform

Every event, in context.

Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.

See the Platform → or email [email protected]